Regeneron Pharmaceuticals Inc (REGN) Options Trading Heats Up on Drug Data

Option volume on Regeneron Pharmaceuticals Inc (REGN) is on track for a yearly high after the company reported promising drug results

Apr 1, 2016 at 10:51 AM
facebook twitter linkedin


Drugmaker Regeneron Pharmaceuticals Inc (NASDAQ:REGN) is up 5.8% to $381.32 today on news that its eczema drug, dupilumab -- a joint venture with Sanofi SA (ADR) (NYSE:SNY) -- showed positive results in two Phase 3 trials. And as the stock makes its biggest upward move in a month, action is heating up in the REGN option pits.

So far today, REGN options are trading at six times their average intraday rate, with calls outnumbering puts by about 2-to-1. In fact, with 2,806 calls and 1,386 puts exchanged so far today, option volume is currently on pace to approach a total of 16,000 contracts -- which would represent a new annual high for the drug stock.

Average daily volume on REGN options tends to be light -- but today's trend toward calls over puts is more of the same. In fact, the security has a Schaeffer's put/call open interest ratio (SOIR) of 0.87 -- which ranks lower than 100% of the past year's worth of readings, as near-term options traders are more call-skewed now than at any other time in the past 12 months.

REGN shares are still down nearly 30% year-to-date -- due in part to poorly received earnings in early February -- and traders who were betting on a bigger rebound may be disappointed. Even with today's bounce, REGN remains under pressure from its descending 40-day moving average. In fact, the stock is currently attempting to close above this trendline for the first time since mid-December.

But Regeneron Pharmaceuticals Inc (NASDAQ:REGN) could get some help challenging this trendline resistance if analysts come around in light of today's news. Specifically, 11 brokerage firms -- more than half of those providing coverage -- rate the stock a "hold" or "strong sell."

Sign up now for Schaeffer's Market Recap to get all the day's big stock movers, must-know technical  levels, and top economic stories straight to your inbox.

 

If you are not making money with options, you aren’t buying options like this…

There is no options strategy that more perfectly approaches trading the fastest moving and most volatile stocks available in the marketplace than this one. In fact, there is no strategy that better utilizes put options for optimal returns and a real trading edge over other traders in the exact same market. New options traders fail out at an incredible rate without proper trade research, execution timing, and option picking. Capitalize on Schaeffer’s 100+ years of options trading excellence with the most coveted product launch in company history. Don't waste another second... join us right now before the next round of trades are released!

SCHAEFFER'S JULY STOCKS REPORT AD
 


 


 
Special Offers from Schaeffer's Trading Partners